Journal article

Preliminary consultation on preferred product characteristics of benzathine penicillin G for secondary prophylaxis of rheumatic fever

Rosemary Wyber, Ben J Boyd, Samantha Colquhoun, Bart J Currie, Mark Engel, Joseph Kado, Ganesan Karthikeyan, Mark Sullivan, Anita Saxena, Meru Sheel, Andrew Steer, Joseph Mucumbitsi, Liesl Zuhlke, Jonathan Carapetis

DRUG DELIVERY AND TRANSLATIONAL RESEARCH | SPRINGER HEIDELBERG | Published : 2016

Abstract

Rheumatic fever is caused by an abnormal immune reaction to group A streptococcal infection. Secondary prophylaxis with antibiotics is recommended for people after their initial episode of rheumatic fever to prevent recurrent group A streptococcal infections, recurrences of rheumatic fever and progression to rheumatic heart disease. This secondary prophylaxis must be maintained for at least a decade after the last episode of rheumatic fever. Benzathine penicillin G is the first line antibiotic for secondary prophylaxis, delivered intramuscularly every 2 to 4 weeks. However, adherence to recommended secondary prophylaxis regimens is a global challenge. This paper outlines a consultation with ..

View full abstract